Welcome to our dedicated page for Sarepta Therapeutics news (Ticker: SRPT), a resource for investors and traders seeking the latest updates and insights on Sarepta Therapeutics stock.
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) is a biotechnology company focused on precision genetic medicine for rare diseases, with a stated leadership position in Duchenne muscular dystrophy and an expanding portfolio across muscle, central nervous system and cardiac conditions. The SRPT news feed on Stock Titan aggregates company-issued updates and market-moving announcements that reflect Sarepta’s scientific, regulatory and financial developments.
Investors and followers of SRPT can use this page to review earnings and revenue updates, such as preliminary net product revenue reports that break out contributions from ELEVIDYS and the company’s PMO franchise, as well as quarterly financial results and commentary on cash position and capital structure. News items also cover clinical and regulatory milestones, including updates to the ELEVIDYS prescribing information, FDA safety labeling decisions, and the design and progress of studies like ENDEAVOR and ESSENCE.
The feed highlights pipeline progress in Sarepta’s next-generation siRNA platform, including clinical trial applications and early-stage data for programs such as SRP-1003 for myotonic dystrophy type 1 and SRP-1005 for Huntington’s disease. It also captures disclosures about strategic restructuring, clinical holds in limb girdle muscular dystrophy gene therapy programs, and collaborations with partners like Arrowhead Pharmaceuticals.
Corporate and capital markets news—such as convertible note exchanges, private placements of common stock, inducement grants under Nasdaq Listing Rule 5635(c)(4), and investor conference presentations—are also included. By reviewing this consolidated SRPT news stream, users can quickly see how Sarepta communicates its progress in genetic medicine, regulatory interactions, financing activities and strategic priorities over time.
Sarepta Therapeutics (NASDAQ:SRPT), a precision genetic medicine company focused on rare diseases, announced the granting of equity awards to 53 new employees hired in Q2 2025. The awards, approved under the company's 2024 Employment Commencement Incentive Plan, include 22,016 stock options at an exercise price of $17.10 per share and 317,317 restricted stock units (RSUs).
The stock options will vest over four years, with 25% vesting after one year and the remainder vesting monthly. The RSUs will vest in four equal annual installments. Both awards are subject to continued employment with Sarepta. These inducement grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).
[]Sarepta Therapeutics (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, announced its senior management will participate in a fireside chat at the BofA Securities Health Care Conference. The event will take place at the Encore Hotel in Las Vegas on May 14, 2025, at 8:40 a.m. PT/11:40 a.m. ET.
The presentation will be available via webcast on Sarepta's investor relations website and will remain archived for 90 days. The company maintains leadership positions in Duchenne muscular dystrophy and limb-girdle muscular dystrophies, while developing a portfolio focused on muscle, central nervous system, and cardiac diseases.
Cash position stood at $647.5M as of March 31, 2025, down from $1.5B at year-end 2024.
Sarepta Therapeutics (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, has scheduled its first quarter 2025 financial results announcement. The results will be released after the Nasdaq Global Market closes on Tuesday, May 6, 2025, followed by a conference call at 4:30 p.m. E.T. to discuss the quarterly performance.
The event will be accessible through a live webcast on the investor relations section of Sarepta's website, with a replay available for one year. Phone participants must register online to receive dial-in details and a personal PIN for accessing the event.